Novartis expands Scemblix label to first-line CML patients

Novartis’ chronic myeloid leukemia drug Scemblix will now be available to newly diagnosed patients, the FDA announced on Tuesday. Scemblix was first approved in 2021 for use as a third-line treatment. But according to the ...